PhereSys Therapeutics

PhereSys Therapeutics is a pre-clinical stage biotechnology company developing a next-generation extracorporeal therapy platform for the selective removal of pathogenic mediators from the blood. Founded by Dr. Robert Langer and Dr. Giovanni Traverso of MIT, the company leverages advanced materials science to target life-threatening inflammatory conditions such as sepsis and cytokine release syndrome. Unlike traditional dialysis or broad-spectrum filtration, PhereSys's technology is designed for high-specificity depletion of harmful cytokines and toxins while preserving essential blood components. The company aims to revolutionize critical care by providing a precision medicine approach to systemic inflammation and immune dysregulation. PhereSys is currently optimizing its proprietary adsorption materials to improve patient outcomes in acute clinical settings.